Amundi’s Mersana Therapeutics MRSN Stock Holding History

Amundi’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3,822	Closed	-$309K	–	2045
2023 Q4	$309K	Buy	+3,822	New	+$154K	﹤0.01%	1528

Other funds holding MRSN

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Amundi's MRSN Position: Q1 2024 in Review

Amundi sold out of Mersana Therapeutics (MRSN) in Q1 2024, closing a stake of 3,822 shares — an estimated $309K sold.

Amundi first reported a position in MRSN in Q4 2023 and held it in 1 quarter. The position peaked at $309K in Q4 2023. 122 funds tracked by Wall St. Rank hold MRSN as of Q1 2024.

Amundi reported no remaining Mersana Therapeutics position as of Q1 2024 after selling out during the quarter.
Amundi sold 3,822 Mersana Therapeutics shares in Q1 2024, an estimated $309K.
Amundi first reported a position in Mersana Therapeutics in Q4 2023 and held it in 1 quarter.
Amundi's Mersana Therapeutics position peaked at $309K in Q4 2023.
122 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2024.

Based on Amundi's 13F filing for Q1 2024, filed 15 May 2024.